Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
First Claim
1. A method of preventing, reducing or treating injury from brain or cerebral ischemia or reperfusion thereof in a patient comprising administering to the patient a C1 inhibitor having a reduced level of terminal sialic acid residues compared to plasma derived human C1 inhibitor and a plasma half-life of less than 6 hours, whereby the C1 inhibitor is administered at least 1 hour after the onset of ischemia and/or at least ten minutes after reperfusion.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
-
Citations
13 Claims
- 1. A method of preventing, reducing or treating injury from brain or cerebral ischemia or reperfusion thereof in a patient comprising administering to the patient a C1 inhibitor having a reduced level of terminal sialic acid residues compared to plasma derived human C1 inhibitor and a plasma half-life of less than 6 hours, whereby the C1 inhibitor is administered at least 1 hour after the onset of ischemia and/or at least ten minutes after reperfusion.
Specification